Study Comparing Vildagliptin Alone or With Metformin for Treating Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes

What this Trial Is About

This research aims to evaluate two different drug treatments for people with nonalcoholic fatty liver disease NAFLD and type 2 diabetes mellitus DM. The study compares vildagliptin alone versus a combination of vildagliptin and metformin to see how they affect NAFLD and insulin resistance over six months. It is a phase 3 randomized clinical trial without any masking or blinding. Participants receive either vildagliptin 50 mg twice daily or a combination of vildagliptin and metformin taken twice daily as part of the study treatment. The study lasts for six months during which these medications are taken regularly. Both treatment groups are closely monitored and compared to assess their effects on liver disease and diabetes management. Throughout the study, participants will have assessments to track improvement in NAFLD and insulin resistance. The main outcome measured is the number of patients showing improvement at six months. Participants will be observed regularly for treatment effects and safety, with no mention of long-term follow-up beyond the study period.

Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM